Jampa Raj 4

What Happened

• Jampa Raj, Chief Technology Officer of Myriad Genetics, was granted 251,889 restricted stock units (RSUs) on June 1, 2026. The filing reports an acquisition price of $0.00 for the award (total reported value $0).
• These RSUs are equity compensation (grant/award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-01; Filing date (Form 4): 2026-06-02 (timely within SEC insider reporting rules).
• Reported price: $0.00 per unit; reported monetary amount: $0 (grant value not shown in filing).
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award consists of time-based restricted stock units under the Issuer's 2017 Equity Incentive Plan. Each RSU equals a contingent right to one share and vests in four equal annual installments beginning on the first anniversary of the grant date.
• No 10b5-1 plan, tax-withholding sale, or exercise noted in this filing.

Context

• RSU grants are standard executive compensation and are intended for retention; they do not represent an immediate purchase or sale of stock. The economic benefit to the insider depends on future vesting and the company's stock price at vesting.
• Retail investors should view this as a compensation-related award rather than a direct bullish or bearish trading signal.